| Issue Date | Title | Author(s) |
| 2023-08-04 | [18F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trial. | Koh, E-S; Gan, HK; Senko, C; Francis, RJ; Ebert, M; Lee, ST; Lau, E; Khasraw, M; Nowak, AK; Bailey, DL; Moffat, BA; Fitt, G; Hicks, RJ; Coffey, R; Verhaak, R; Walsh, KM; Barnes, EH; De Abreu Lourenco, R; Rosenthal, M; Adda, L; Foroudi, F; Lasocki, A; Moore, A; Thomas, PA; Roach, P; Back, M; Leonard, R; Scott, AM |
| 2023-12-06 | Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer. | Buteau, JP; Moon, D; Fahey, MT; Roberts, MJ; Thompson, J; Murphy, DG; Papa, N; Mitchell, C; De Abreu Lourenco, R; Dhillon, HM; Kasivisvanathan, V; Francis, RJ; Stricker, P; Agrawal, S; O'Brien, J; McVey, A; Sharma, G; Levy, S; Ayati, N; Nguyen, A; Lee, S-F; Pattison, DA; Sivaratnam, D; Frydenberg, M; Du, Y; Titus, J; Lee, S-T; Ischia, J; Jack, G; Hofman, MS; Emmett, L |
| 2020-12-16 | Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial. | de Feria Cardet, RE; Hofman, MS; Segard, T; Yim, J; Williams, S; Francis, RJ; Frydenberg, M; Lawrentschuk, N; Murphy, DG; De Abreu Lourenco, R |
| 2018-11-01 | A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol | Hofman, MS; Murphy, DG; Williams, SG; Nzenza, T; Herschtal, A; De Abreu Lourenco, R; Bailey, DL; Budd, R; Hicks, RJ; Francis, RJ; Lawrentschuk, N |
